Grant: Engage Plus Grants Program
University of British Columbia
$12,484.00
Characterizing the impact of a novel therapeutic on the infection strategy of pathogens
EF 2016-17
Résumé
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Michael Murphy in the fields of protein biochemistry, biophysics, and structural biology. Thisproject proposes to: (1) optimize the protein purity and yields of NovoBind's novel antibodies and antigens inorder to conduct unique proof of concept experiments, (2) measure the strength of binding between antibodiesand antigens, and (3) begin to map the interaction between the most promising antibody/antigen combinations.The development of a Salmonella-selective and highly effective antibody would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
501378-2016
Name nom
Murphy, Michael
Department département
Microbiology and Immunology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
12484
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Characterizing the impact of a novel therapeutic on the infection strategy of pathogens
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Michael Murphy in the fields of protein biochemistry, biophysics, and structural biology. Thisproject proposes to: (1) optimize the protein purity and yields of NovoBind's novel antibodies and antigens inorder to conduct unique proof of concept experiments, (2) measure the strength of binding between antibodiesand antigens, and (3) begin to map the interaction between the most promising antibody/antigen combinations.The development of a Salmonella-selective and highly effective antibody would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.